Does atrial fibrillation in elderly patients with chronic heart failure limit the efficacy of carvedilol? Suggestions from an observational study

Italian Heart Journal

Volumn 6, Issue 4, 2005, Pages 323-327

  Opasich, Cristina ^a   De Feo, Stefania ^a   Cioffi, Giovanni ^b   Pulignano, Giovanni ^c   Del Sindaco, Donatella ^d   Tarantini, Luigi ^e   Gualco, Alessandra ^a   Patrignani, Anna ^a  

^a IRCCS   (Italy)

^b Villa Bianca Hospital   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d INRCA   (Italy)

^e SAN MARTINO HOSPITAL   (Italy)

Author keywords

Atrial fibrillation; Carvedilol; Elderly; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CARVEDILOL; PROPANOLAMINE DERIVATIVE;

AGE; AGED; ANALYSIS OF VARIANCE; ARTICLE; CASE CONTROL STUDY; CHRONIC DISEASE; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PROBABILITY; PROSPECTIVE STUDY; REFERENCE VALUE; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ATRIAL FIBRILLATION; CARBAZOLES; CASE-CONTROL STUDIES; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROBABILITY; PROPANOLAMINES; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 23044435492     PISSN: 1129471X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Foody JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: scientific review. JAMA 2002; 287: 883-9.
2. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
3. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
4. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55.
5. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11 942 elderly patients with heart failure. Am J Med 2002; 113: 650-6.
6. Shibata MC, Flather MD, Bohm M, et al. Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design. Int J Cardiol 2002; 86: 77-85.
7. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87 (Suppl): VI102-VI110.
8. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344: 493-8.
9. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy on Congestive Heart Failure. N Engl J Med 1995; 333: 77-82.
10. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314: 1547-52.
11. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10.
12. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341: 857-65.
13. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 1991; 84: 40-8.
14. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998; 158: 229-34.
15. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-52.
16. Dries DL, Exner DV, Gersh BJ, Domanski MI, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality anal heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Chyle Cardiol 1998; 32: 695-703.
17. Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001; 142: 498-501.
18. Fung JW, Chan SK, Yeung LY, Sanderson JE. Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials. Eur J Heart Fail 2002; 4: 489-94.
19. Cioffi G, Stefenelli C, Tarantini L, Opasich C. Prevalence, predictors, and prognostic implications of improvement in left ventricular systolic function and clinical status in patients > 70 years of age with recently diagnosed systolic heart failure. Am J Cardiol 2003; 92: 166-72.
20. Arnold RH, Kotlyar E, Hayward C, Keogh AM, Macdonald PS. Relation between heart rate, heart rhythm, and reverse left ventricular remodelling in response to carvedilol in patients with chronic heart failure: a single centre, observational study. Heart 2003; 89: 293-8.
21. Schleman KA, Lindenfeld JA, Lowes BD, et al. Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. J Card Fail 2001; 7: 4-12.
22. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103: 1428-33.
23. Wedel H, Demets D, Deedwania P, et al, for the MERIT-HF Study Group. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. Am Heart J 2001; 142: 502-11.
24. Deedwania PC, Gottlieb S, Ghali JK, Waagstein F, Wikstrand JC, for the MERIT-HF Study Group. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004; 25: 1300-9.
25. Palazzuoli A, Bruni F, Puccetti L, et al. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail 2002; 4: 765-70.
26. Konstam MA, Kronenberg MW, Rousseau MF, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation 1993; 88: 2277-83.
27. Rochon PA, Tu JV, Anderson GM, et al. Rate of heart failure and 1-year survival for older people receiving low-dose beta-blocker therapy after myocardial infarction. Lancet 2000; 356: 639-44.
28. Metha PA, McDonagh S, Poole-Wilson PA, Grocott-Mason R, Dubrey SW. Heart failure in a district general hospital: are target doses of beta-blockers realistic? QJM 2004; 97: 133-9.